Thymosin beta-4 and TB-500 should not be used as interchangeable labels without checking the molecule. A full-length peptide, a fragment and a commercial product using a shorthand name can have different properties and evidence.

The October 2026 HHS appendix defines a particular TB-500 fragment. HHS draft 503A peptide policy and appendices By contrast, a randomized ophthalmic study investigated full-length thymosin beta-4 for dry-eye outcomes. Thymosin beta-4 ophthalmic solution: randomized phase 2 trial The human trial is relevant to that studied preparation and indication. It does not validate the fragment for general tissue repair or systemic use.

This identity issue is more fundamental than whether a study sounds promising. If the cited paper uses a different molecule, its results cannot be assigned to a product simply because both names are associated with the same parent protein. Sequence, chemical modification and formulation need to match the claim or the difference must be explained.

The route and disease setting also matter. A local eye preparation is not a model for every wound or musculoskeletal injury. Clinical endpoints in dry-eye research do not establish tendon repair, muscle recovery or whole-body regeneration.

A careful evidence review should create a separate record for each exact agent. Include molecular identity, formulation, species or patient population, route, endpoint and safety observations. Then identify whether any direct clinical evidence actually matches the proposed use. Where it does not, describe the connection as a hypothesis.

This article provides no recommendation for TB-500 or thymosin beta-4. It is an identity and evidence guide designed to prevent an attractive but invalid shortcut from one paper to another product. Medical, analytical and regulatory specialists should review any claim before public release.